Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: Interactions with antihypertensive therapy

Urology

Volumn 53, Issue 3 SUPPL. A, 1999, Pages 14-20

  Tewari, Ashutosh ^a   Narayan, Perinchery ^b  

^a Josephine Ford Cancer Center   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

USA

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; TAMSULOSIN; TERAZOSIN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; HYPERTENSION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

EID: 0033021795     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00534-2     Document Type: Article

References (88)

1. U.S. Bureau of the Census. Report 12/28/98 statistic.
2. Barry M.J., Cockett A.T., Holtgrewe H.L., et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 150:1993;351-358.
3. Barry M.J., Fowler F.J. Jr, Bin L., et al. A nationwide survey of practicing urologists current management of benign prostatic hyperplasia and clinically localized prostate cancer . J Urol. 158:1997;488-491.
4. Barry M.J., Fowler F.J. Jr, O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 148:1992;1549-1557.
5. McConnell JD, Barry MJ, and Bruskewitz RC: Clinical Practice Guidelines: Quick Reference Guide for Clinicians. Benign prostatic hyperplasia: diagnosis and treatment. Bethesda, MD: Agency for Health Care Policy and Research 8: 1-17, 1994.
6. Sagnier P.P., Girman C.J., Garraway M., et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol. 29:1996;15-20.
7. Guess H.A., Jacobsen S.J., Girman C.J., et al. The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia. Med Care. 33:1995;As26-As35.
8. Collins M.M., Barry M.J., Bin L., et al. Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians. J Gen Intern Med. 12:1997;224-229.
9. Monane M., Bohn R.L., Gurwitz J.H., et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance results from a population-based study in the elderly . Am J Hypertens. 10:1997;697-704.
10. He J., Whelton P.K. Epidemiology and prevention of hypertension. Med Clin North Am. 81:1997;1077-1097.
11. Sadowski A.V., Redeker N.S. The hypertensive elder a review for the primary care provider . Nurse Pract. 21:1996;99-102.
12. Siegal D., Lopez J. Trends in anti-hypertensive drug use in the United States Do the JNC-V recommendations effect prescribing? JAMA. 278:1997;1745-1748.
13. Walma E.P., Hoes A.W., van Dooren C., et al. Withdrawal of long-term diuretic medication in elderly patients a double blind randomised trial . Br Med J. 315:1997;464-468.
14. McCombs J.S., Nichol M.B., Newman C.M., et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 32:1994;214-226.
15. Narayan P., Tewari A. Overview of α blocker therapy for benign prostatic hyperplasia. Urology. 51:(suppl):1998;38-45.
16. Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology. 32:1988;16-20.
17. Eckert R.E., Schreier U., Drescher P., et al. Regulation of prostatic smooth muscle contractility by intracellular second messengers implications for the conservative treatment of benign prostatic hyperplasia . Urol Int. 54:1995;6-21.
18. Abrams P., Donovan J.L., de la Rosette J.J., et al. International Continence Society "Benign Prostatic Hyperplasia" Study background, aims, and methodology . Neurourol Urodyn. 16:1997;79-91.
19. Akimoto Y., Sono K., Kurahashi K., et al. Effects of specific alpha-adrenoceptive agents on extraneuronal uptake (uptake 2) of isoproterenol in perfused rat heart. Life Sci. 44:1989;945-950.
20. Andersson K.E., Lepor H., Wyllie M.G. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 30:1997;202-215.
21. Appell R.A. Pathogenesis and medical management of benign prostatic hyperplasia. Semin Nephrol. 14:1994;531-543.
22. Brune M.E., Katwala S.P., Milicic I., et al. Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. Pharmacology. 53:1996;356-368.
23. Bultmann R., Kurz A.K., Starke K. Alpha 1-adrenoceptors and calcium sources in adrenergic neurogenic contractions of rat vas deferens. Br J Pharmacol. 111:1994;151-158.
24. Bylund D.B., Eikenberg D.C., Hieble J.P., et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 46:1994;121-136.
25. Chapple C.R., Aubry M.L., James S., Greengrass P.M., et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol. 63:1989;487-496.
26. Drescher P., Eckert R.E., Sparwasser C., et al. Alpha-1 receptor mediated smooth muscle regulation in benign prostatic hyperplasia. Scand J Urol Nephrol. 157:(suppl):1994;33-40.
27. 3H]prazosin binding sites . J Pharm Pharmacol. 41:1989;714-716.
28. 1 antagonists. Br J Urol. 81:(suppl 1):1998;48-50.
29. Carruthers S.G. Adverse effects of alpha 1-adrenergic blocking drugs. Drug Saf. 11:1994;12-20.
30. Daly C.J., McGrath J.C., Wilson V.G. Pharmacological analysis of postjunctional alpha-adrenoceptors mediating contractions to (-)-noradrenaline in the rabbit isolated lateral saphenous vein can be explained by interacting responses to simultaneous activation of alpha 1- and alpha 2-adrenoceptors. Br J Pharmacol. 95:1988;485-500.
31. Hedlund H., Andersson K.E., Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 130:1983;275-278.
32. Jonler M., Riehmann M., Bruskewitz R.C. Benign prostatic hyperplasia Current pharmacological treatment . Drugs. 47:1994;66-81.
33. Kirby R.S., Coppinger S.W., Corcoran M.O., et al. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol. 60:1987;136-142.
34. Yamaguchi O., Shiraiwa Y., Kobayashi M., et al. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol Int. 45:(suppl 1):1990;40-46.
35. Roehrborn C.G., Siegel R.L., Kaplan S.A., et al. Safety and efficacy of doxazosin in benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies . Urology. 48:1996;406-415.
36. Gillenwater J.Y., Conn R.L., Chrysant S.G., et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension a double-blind, placebo-controlled, dose-response multicenter study . J Urol. 154:1995;110-115.
37. Elhilali M.M., Ramsey E.W., Barkin J., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 47:1996;335-342.
38. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 47:1996;159-168.
39. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology. 45:1995;406-413.
40. Fawzy A., Braun K., Lewis G.P., et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients a multicenter study . J Urol. 154:1995;105-109.
41. Lepor H., Kaplan S.A., Klimberg I., et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol. 157:1997;525-530.
42. Wilde M.I., McTavish D. Tamsulosin A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia . Drugs. 52:1996;883-898.
43. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 06877: Tamsulosin hydrochloride drug package insert, 1998.
44. Abrams P., Schulman C.C., Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 76:1995;325-336.
45. Chapple C.R., Wyndaele J.J., Nordling J., et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 29:1996;155-167.
46. Chapple C.R. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia rationale and clinical experience . Eur Urol. 29:1996;129-144.
47. Miyatake R, Park YC, Koike H, et al: Urodynamic evaluation of alpha-1 blocker tamsulosin on benign prostatic hyperplasia using pressure-flow study. Nippon Hinyokika Gakkai Zasshi 87: 1048-1055, 1996. (In Japanese).
48. Okada H., Kawaida N., Ogawa T., et al. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group. Scand J Urol Nephrol. 30:1996;379-385.
49. Schulman C.C., Cortvriend J., Jonas U., et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 29:1996;145-154.
50. Sudoh K., Tanaka H., Inagaki O., et al. Effect of tamsulosin, a novel alpha 1-adrenoceptor antagonist, on urethral pressure profile in anaesthetized dogs. J Auton Pharmacol. 16:1996;147-154.
51. Carter B.L. Current recommendations of the Joint National High Blood Pressure Committee. Clin Pharmacol. 12:1993;53-57.
52. Chalmers J. Treatment guidelines in hypertension current limitations and future solutions . J Hypertens. 14:(suppl):1996;S3-S8.
53. Frohlich E.D. Detection, evaluation, and treatment of hypertension JNC-5 (Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure) [editorial] . Heart Dis Stroke. 2:1993;459-460.
54. Frohlich E.D. Continuing advances in hypertension the Joint National Committee's fifth report . Am J Med Sci. 310:(suppl 1):1995;S48-S52.
55. Abernethy D.R. Pharmacological properties of combination therapies for hypertension. Am J Hypertens. 10:1997;13S-16S.
56. Fishkind D., Paris B.E., Aronow W.S. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 45:1997;809-812.
57. Ooi H.H., Coleman P.L., Duggan J., et al. Treatment of hypertension in the elderly. Curr Opin Nephrol Hypertens. 6:1997;504-509.
58. Valvo E., Angelo A.D., Maschio G. Diuretics in hypertension. Kidney Int. 59:(suppl):1997;S36-S38.
59. Kaplan N.M., Gifford R.W. Jr. Choice of initial therapy for hypertension. JAMA. 275:1996;1577-1580.
60. Hansson L. Success in the treatment of hypertension a status report . J Hypertens. 15:(suppl):1997;S11-S15.
61. Gavras I, Manolis A, and Gavras H: Drug therapy for hypertension. Am Fam Physician 55: 1823-1826, 1829-1834, 1997.
62. Freis E.D. Current status of diuretics, beta-blockers, alpha-blockers, and alpha-beta-blockers in the treatment of hypertension. Med Clin North Am. 81:1997;1305-1317.
63. Bulpitt C.J., Palmer A.J., Beavers D.G., et al. Calcium channel blockers and cardiac mortality in the treatment of hypertension a report from the Department of Health Hypertension Care Computing Project (DHCCP) . J Hum Hypertens. 11:1997;205-211.
64. Dougall H.T., McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 15:1996;91-106.
65. Epstein M. Calcium channel blockers and hypertension evolving perspective-1996 . Cardiovasc Drugs Ther. 10:(suppl 3):1997;883-891.
66. Opie L.H. Calcium channel blockers summary and safety issues . Cardiovasc Drugs Ther. 10:(suppl 3):1997;893-895.
67. Palma Gamiz J.L. High blood pressure and calcium antagonism. Cardiology. 88:(suppl 1):1997;39-46.
68. Philipp T., Anlauf M., Distler A., et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. Br Med J. 315:1997;154-159.
69. Zanchefti A: Current position of calcium antagonists in hypertension. J Hypertens 14(suppl: S11-S15, 1996.
70. Plosker G.L., Faulds D. Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. Drugs. 52:1996;232-253.
71. Gifford R.W. Jr. Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. Med Clin North Am. 81:1997;1319-1333.
72. Langtry H.D., Markham A. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging. 10:1997;131-166.
73. Mancia G., Omboni S., Grassi G. Combination treatment in hypertension: the VeraTran Study. Am J Hypertens. 10:1997;153s-158s.
74. McAlister F.A., Teo K.K., Lewanczuk R.Z., et al. Contemporary practice patterns in the management of newly diagnosed hypertension. Can Med Assoc J. 157:1997;23-30.
75. Moser M. Management of hypertension, Part II. Am Fam Physician. 53:1996;2553-2560.
76. Preuss H.G., Burris J.F. Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Drug Saf. 14:1996;355-364.
77. Rosenthal J., Bahrmann H., Benkert K., et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Cardiology. 87:1996;409-414.
78. Schaefer K.L., Porter J.A. Angiotensin II receptor antagonists the prototype losartan . Ann Pharmacother. 30:1996;625-636.
79. Small R.E., Freeman Arnold S.B., Goode J.V., et al. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors a comparison of older and newer agents . Pharmacotherapy. 17:1997;1011-1016.
80. Wagstaff A.J., Davis R., McTavish D. Fosinopril a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension . Drugs. 51:1996;777-791.
81. Waeber B., Burnier M., Nussberger J., et al. Experience with angiotensin II antagonists in hypertensive patients. Clin Exp Pharmacol Physiol. 3:(suppl):1996;S142-S146.
82. Randomised controlled trial of treatment for mild hypertension: design and pilot trial. Report of Medical Research Council Working Party on Mild to Moderate Hypertension . Br Med J. 274:1977;1437-1440.
83. Cauffield JS, Gums JG, and Curry RW Jr: Alpha blockers: a reassessment of their role in therapy. Am Fam Physician 54: 263-266, 269-70, 1996.
84. Gifford R.W. Jr. Managing hypertension in the elderly dispelling the myths . Cleve Clin J Med. 62:1995;29-35.
85. Moser M. Management of hypertension, Part I. Am Fam Physician. 53:1996;2295-2302.
86. Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens. 10:1997;2s-8s.
87. Pogue V.A., Ellis C., Michel J., et al. New staging system of the fifth Joint National Committee report on the detection, evaluation, and treatment of high blood pressure (JNC-V) alters assessment of the severity and treatment of hypertension. Hypertension. 28:1996;713-718.
88. Khoury A.F., Kaplan N.M. Alpha-blocker therapy of hypertension. An unfulfilled promise. JAMA. 266:1991;394-398.